Open AccessTivozanib (Fotivda®)
Author(s) -
Michelle Sproat
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000789328.80500.8b
Subject(s) - sorafenib , medicine , renal cell carcinoma , tyrosine kinase inhibitor , refractory (planetary science) , tyrosine kinase , cancer research , kinase , oncology , cancer , receptor , chemistry , biology , biochemistry , astrobiology , hepatocellular carcinoma